Hyphens Pharma News Today

/PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapores leading...

ALB Asia 40 Under 40 continues its tradition of recognising exceptional legal talent across Asia, selected from 600 outstanding nominees. The lawyers featured on the list represent diverse jurisdictions and practice areas. They were meticulously chosen through a rigorous selection process, evaluating their work quality, client and colleague recommendations, and their potential for future growth.

ALB Asia 40 Under 40 continues its tradition of recognising exceptional legal talent across Asia, selected from 600 outstanding nominees. The lawyers featured on the list represent diverse jurisdictions and practice areas. They were meticulously chosen through a rigorous selection process, evaluating their work quality, client and colleague recommendations, and their potential for future growth.

Key Insights The projected fair value for Hyphens Pharma International is S$0.50 based on Dividend Discount Model...

In its inaugural list, Asian Legal Business presents thenext generation of the country’s lawyers who have demonstrated great potential in the industry, while earning wide acclaim from their clients in the process. The list is in alphabetical order and some lawyers have been profiled.

Market Study on ePharmacy: Venture Capitalist Fundings in ePharmacy Market to Swell Revenue

Winlevi is a first-in-class topical drug for the treatment of acne approved by U.S. FDA in August 2020.It will reinforce our Proprietary Brand segment's dermatological franchise. SINGAPORE,

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement21-Dec-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland & Singapore – 21 December 2022: Cosmo Pharmaceutica...

Two large, randomized trials show no reduced risk of COVID-19, respiratory infections with vitamin D supplementation.

Baricitinib 4 mg met the primary endpoint in a phase 3 study involving patients with AD who had failed or could not take cyclosporine.